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Malignancies represent one of the main aetiologies of pleurisies.
Carcinoma of any organ can metastasize to the pleura but the cancers
most concerned are lung and breast carcinomas, lymphomas and, less
frequently, digestive and ovary carcinomas (Serre et al, 1990; Fenton
and Richardson, 1995; Sahn, 1988). Pleural mesothelioma also
occurs rarely but its frequency is increasing (Peto et al, 1995).
Since in about 40% of malignant effusions cytological examina-
tion of pleural fluid does not allow the detection of tumour cells
(Loddenkemper and Boutin, 1993; Fenton and Richardson, 1995;
Harris et al, 1995; Sahn, 1988), several authors investigated the assay
of tumour markers in pleural fluid in order to improve the diagnostic
performances. Carcinoembryonic antigen (CEA) has been studied
the most and has shown a diagnostic sensitivity of about 50–60%
(Rapellino et al, 1990). Nevertheless, for a particular carcinoma the
use of a single marker appeared insufficient because it is not always
expressed and, in addition, no tumour marker has a spectrum wide
enough to detect all types of malignancies. Thus, many studies
emphasized the association of CEA with various tumour markers
such as carbohydrate antigens 15–3, 19–9 and 72–4 (CA 15–3, CA
19–9 and CA 72–4) (Ferroni et al, 1990; Villena et al, 1996). The best
results were logically obtained in adenocarcinomas since serum CA
15–3 is proposed for the management of breast adenocarcinomas
(Soletormos et al, 1996), CA 72–4 for gastric and ovarian adeno-
carcinomas (Guadagni et al, 1995) and CA 19–9 for digestive adeno-
carcinomas (Grem, 1997). CYFRA 21–1, a serum assay for soluble
fragments of cytokeratin 19, was recently proposed for the diagnosis
and the follow-up of non-small-cell lung carcinomas (Pujol et al,
1993; Plebani et al, 1995) but also for squamous cell carcinomas of
the head and neck (Doweck et al, 1995) and uterine cervix (Callet et
al, 1998) and lastly in bladder cancer (Morita et al, 1997). Moreover,
we recently described high values of this marker in the pleural fluid
of patients with mesothelioma (Salama et al, 1998).
Within these numerous studies of tumour markers in malignant
effusions, the use of various non-equivalent assays and the
heterogeneity or the small size of the samples of patients make
comparison of the results difficult and generalization impossible.
Furthermore, depending on the studies, statistical analyses and
pleural threshold determinations varied greatly (Rapellino et al,
1990); the worst solution, i.e. the use of serum thresholds, being
chosen in numerous cases. Indeed, at the same level of specificity,
pleural and serum thresholds are different, as shown for CEA
(Rittgers et al, 1978, Romero et al, 1996) and also for CYFRA
(Toumbis et al, 1996). In patients with malignant effusions, pleural
values of markers are higher than serum values and the greater
sensitivity of the pleural assay for the diagnosis of malignancy was
demonstrated for several markers such as CEA (Rittgers et al,
1978; Klockars et al, 1980; Asseo and Tracopoulos, 1982;
Rapellino et al, 1990; Romero et al, 1996), CA 15–3 (Rapellino et
al, 1990) or neuron-specific enolase (NSE) (Menard et al, 1993).
For all these reasons, in the present study, we evaluated in
pleural fluid a large panel of tumor markers including CEA, CA
15–3, CA 72–4 and CA 19–9, regarding their interest in adenocar-
cinomas, and CYFRA, for its interest in squamous cell carcinomas
and mesotheliomas. We also analysed squamous cell carcinoma
antigen (SCC) and NSE, serum markers of squamous cell carci-
nomas (Niklinski and Furman, 1995; Callet et al, 1998) and small-
cell lung carcinomas (Niklinski and Furman, 1995; Plebani et al,
1995) respectively. Our objective was to determine the optimal
panel able to improve the diagnosis of malignant effusions, partic-
ularly in cytologically negative effusions. This study is, to our
knowledge, the first where all these markers were evaluated
together and in such a large series of patients.
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Patients
We retrospectively studied 336 pleural effusions collected from
patients of the Department of Internal Medicine of Purpan
Hospital in Toulouse, France (Table 1). Part of this series was
constituted of 156 available effusions (out of 199) used in a
previous report to evaluate pleural CYFRA in the diagnosis of
malignant effusions (Salama et al, 1998). This series was
completed by 180 pleural effusions with perfectly defined
aetiology, obtained from July 1996 to December 1997.
In a control group of 121 patients (62.2% men, aged from 10 to
95 years, median 71 years), a benign disease was diagnosed and
confirmed by follow-up and/or efficiency of a specific treatment.
Malignant pleural involvement was ascertained in 215 patients
(52.1% men, aged from 19 to 89 years, median 65 years), by the
presence of malignant cells in pleural fluid and/or in pleural
biopsy (blind needle biopsy or biopsy under thoracoscopy). These
two groups were representative of the main causes of pleurisies
(Serre et al, 1990; Fenton and Richardson, 1995; Villena et al,
1996; Sahn, 1988). Breast and lung cancer were the most frequent
causes of malignant pleural involvement. Malignant effusions of
unknown primary site were frequent in our recruitment (46 out of
215, i.e. 21%) in agreement with the prospective study of Villena
et al (1996) (17 out of 65, i.e 26%).
Cytological analysis and tumour marker assay
Pleural fluid was obtained by thoracocentesis, collected in sterile
tubes without anticoagulant and rapidly brought to the laboratory.
After performing a cell count of the sample of pleural fluid with a
haemocytometer, optimal dilution was carried out in order to
obtain 300 nucleated cells ml–1 and several samples of 0.7 ml were
cytocentrifuged at 700 rpm for 17 min in a Cytospin 2™ (Shandon
Ltd, Cheshire, UK). Air-dried slides were stained with the
May–Grünwald–Giemsa method, and absolute ethanol-fixed
slides were stained with the Papanicolaou method, for morpho-
logical examination. Periodic acid-Schiff and Alcian blue (pH 2.5)
cytochemical reactions and immunocytochemical analysis, using a
panel of monoclonal antibodies to CEA, cytokeratins, vimentin,
epithelial membrane antigen, desmin, B72–3 and Ber EP4, were
also performed on the slides to aid the characterization of suspect
and malignant cells (Serre et al, 1990; Daste et al, 1991). Part of
the sample was centrifuged and the supernatant aliquoted and
stored at –80°C until tumour markers were assayed with commer-
cial enzyme immunoassays: CEA, CA 19–9 (Axsym System®,
Abbott Diagnostic, France), SCC (IMX System®, Abbott
Diagnostic, France), CYFRA and CA 72–4 (Enzymun-Test®,
Boehringer Mannheim, France), CA 15–3 and NSE (CPE-CA
15–3® and CPE-NSE®, Cis Bio International, France). The tumour
markers were assayed in duplicate and dilutions were carried out,
if necessary, with the appropriate diluent as recommended by the
manufacturer.
Data analysis
Descriptive statistics and discriminant analysis were performed
using STATISTICA 5.1 (StatSoft, Inc, Tulsa, OK, USA). The
median and range of each marker were determined in the groups of
benign and malignant effusions. Differences between groups were
tested with Mann–Whitney’s U-test. Pleural thresholds were
defined, in the group of benign effusions, at various levels of diag-
nostic specificities. Corresponding levels of sensitivities were
determined in various groups of malignant effusions. Receiver
Operating Characteristic curves were also constructed for each
marker and the areas under the curves were compared (Hanley and
McNeil, 1983). Discriminant analysis constitutes a powerful tool
to choose, among many parameters, the optimal combination of
two or more of them which is able to separate groups in a popula-
tion. This approach was previously applied to the evaluation of
tumour markers, particularly to distinguish small-cell lung cancer
from non-small-cell lung cancer (Paone et al, 1996). Thus, we
performed discriminant analysis, after logarithmic transformation
of the values, to determine which markers are significantly able to
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aIncluding uterus (2) and kidney (1) adenocarcinoma. bIncluding skin (1),
uterus (2) and head and neck (1) squamous cell carcinoma. cIncluding
bladder carcinoma (3), and digestive and lung carcinoid tumour (2).
dIncluding systemic lupus erythematosus (3), rheumatoid arthritis (2),
Gougerot-Sjögren’s syndrome (1), scleroderma (1), Sharp’s syndrome (1)
and Still’s disease (1). eIncluding post-traumatic (9), pulmonary embolism (5),
benign asbestosis (3), chylothorax (1), lung fibrosis (1), cirrhosis (5),
nephrotic syndrome (1) and sarcoidosis (1).
Table 2 Median and range of tumour markers in benign and malignant
effusions
Tumour markers Benign effusions Malignant effusions P
n=121 n=215
CEA (ng ml–1) 1 (0–6.2) 17.2 (0.2–12785) < 0.00001
CA 72-4 (U ml–1) 2 (1.6–4.5) 21.8 (1.6–20000) < 0.00001
CA 15-3 (U ml–1) 13.5 (2–50.8) 68.9 (0.5–3581) < 0.00001
CA 19-9 (U ml–1) 1.2 (0–550.3) 5.9 (0–480000) < 0.00001
CYFRA (ng ml–1) 16.3 (0–188.4) 107.4 (1.8–12796.5) < 0.00001
NSE (ng ml–1) 3.3 (0.1–375) 7.3 (0–408) < 0.00001
SCC (ng ml–1) 1.6 (0–38.4) 2.2 (0–2420) 0.22separate benign from malignant effusions. Then the diagnostic
sensitivity and specificity of their association were evaluated. We
also searched for a discriminant combination of markers able to
predict the histological type and the primary site of the tumour of
origin. Differences were considered significant for P ≤ 0.01.
RESULTS
Tumour markers in benign and malignant effusions
The median and range of each marker in benign and malignant
effusions are summarized in Table 2. Except for SCC, the distribu-
tion of the values appeared significantly higher in malignant than
in benign effusions. Considering the subclasses of benign effu-
sions, we observed a significant but moderate elevation of NSE
and CA 15–3 in the group of patients with tuberculosis and very
high values for NSE in the two patients with rheumatoid arthritis.
Diagnostic indexes
The performance of each marker at various levels of specificity
was analysed by comparing areas under the receiver operating
characteristic curves (Figure 1). The areas of CA 72–4, CEA, CA
15–3 and CYFRA appeared similar and significantly higher than
those of CA 19–9 and NSE, themselves greater than the area of
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Table 3 Thresholds and diagnostic sensitivity (percentage) of the seven tumour markers in the various groups of malignant effusions
n CEA CA 15-3 CYFRA CA 19-9 CA 72-4 SCC NSE
Thresholdsa 6 ng ml–1 36.2 U ml–1 163 ng ml–1 219 U ml–1 3.4 U ml–1 27 ng ml–1 18.1 ng ml–1
All malignant effusions 215 60.0 63.7 42.8 20.9 68.4 5.6 18.1
Non-lymphomatous 197 65.5 68.5 46.7 22.8 73.1 6.1 18.8
Carcinomas 183 70.5 71.0 47.0 24.6 78.7 6.6 18.0
Adenocarcinomas 154 75.3 77.9 52.6 26.6 85.1 3.2 12.3
Squamous cell carcinomas 11 54.5 63.6 27.3 18.2 72.7 63.6 9.1
Small-cell lung carcinomas 13 53.8 7.7 7.7 15.4 30.8 0.0 92.3
Miscellaneous 5 0.0 40.0 20.0 0.0 20.0 0.0 20.0
Mesotheliomas 11 0.0 45.5 54.5 0.0 0.0 0.0 9.1
Sarcomas 3 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Lymphomas 18 0.0 11.1 0.0 0.0 16.7 0.0 11.1
aThresholds were chosen to determine a diagnostic specificity of 99% (except for NSE: 97.5%).
Table 4 Diagnostic sensitivity (percentage) of the association CEA, CA 15-3, CYFRA and NSE in the various groups of malignant
effusions considering all the effusions and only the cytologically negative effusions, with an overall diagnostic specificity of 95%
All effusions Cytologically negative effusions
n Sensitivity n Sensitivity
All malignancies 215 88.4 35 74.3
Non-lymphomatous 197 94.4 31 83.9
Carcinomas 183 95.6 23 87.0
Adenocarcinomas 154 97.4 19 94.7
Squamous cell carcinomas 11 81.8 2 50.0
Small cell lung carcinomas 13 100.0 0 –
Miscellaneous 5 60.0 2 50.0
Mesotheliomas 11 72.7 7 71.4
Sarcomas 3 100.0 1 100.0



























Figure 1 Receiver operating characteristic curves for each tumour marker
considering the group of benign effusions for specificity and the group of non-
lymphomatous effusions for sensitivity. The areas under the curves were
similar for CA 72-4, CA 15-3, CEA and CYFRA (0.884, 0.880, 0.871 and
0.868 respectively), significantly higher than the areas of CA 19-9 and NSE
(0.714 and 0.698) themselves significantly higher than the area of SCC
(0.589)SCC. Thresholds determined at a diagnostic specificity of 99%
(except for NSE for which the 97.5% specificity threshold yielded
a clearly higher sensitivity) and the corresponding diagnostic
sensitivities in the various histological groups of malignant effu-
sions are listed in Table 3. In carcinomas, the best results were
observed for CEA, CA 72–4, CA 15–3 and CYFRA while, in
mesotheliomas, only CYFRA and CA 15–3 showed high sensi-
tivities. NSE exhibited a very high sensitivity in small-cell lung
carcinomas and in some rare malignancies such as sarcomas, while
SCC was only seen to be useful in the diagnosis of squamous cell
carcinomas.
Combinations of markers
Discriminant analysis was used to identify a minimum number of
markers able to classify benign versus non-lymphomatous malig-
nant effusions. CEA, CA 15–3, CYFRA and NSE appeared
significantly discriminant (P < 0.002). By contrast, CA 19–9, SCC
but also CA 72–4, despite its high individual sensitivity, did not
appear significantly contributive (P > 0.1). Table 4 reports the
sensitivities of the panel (CEA + CA 15–3 + CYFRA + NSE) in
various groups of malignant effusions, with the 99% specificity
thresholds for CEA, CA 15–3 and CYFRA and the 97.5% speci-
ficity threshold for NSE. A result was considered positive if at
least one marker was above its threshold. For the association, the
high levels of individual specificity led to an overall specificity
remaining high at 95% while we noted a significant improve-
ment in overall sensitivity in non-lymphomatous malignancy
at 94.4%.
Tumour markers in cytologically negative effusions
We applied the same approach to cytologically negative effusions
whose neoplastic origin was ascertained by more invasive
methods such as blind needle biopsy or biopsy under thora-
coscopy. The diagnostic performance of CEA, CA 15–3, CYFRA
and NSE remained very convincing in this situation since it
allowed the detection of 26 out of 31 (83.9%) cytologically nega-
tive non-lymphomatous malignant effusions (Table 4).
Tumour markers and origin of the primary site
The ability of tumour markers to predict the main histological types
or the primary site of the tumour was investigated by discriminant
analysis. NSE, SCC and CYFRA appeared to be the most contribu-
tive to differentiate adenocarcinomas, small-cell lung carcinomas,
squamous cell carcinomas and mesotheliomas. A correct prediction
was achieved in 89.4% of the cases, with the best results in adeno-
carcinomas and small-cell lung carcinomas (Table 5).
Mesotheliomas were greatly misclassified since the association of
high CYFRA and/or CA 15–3 values to low levels of CEA found in
mesotheliomas was also seen in some adenocarcinomas. Concerning
the primary site of adenocarcinomas, CEA, CA 15–3, CA 19–9 and
NSE were the most significant markers but only 64.8% of adenocar-
cinomas with a known primary site were correctly classified
(Table 6).
DISCUSSION
Seven tumour markers were evaluated in pleural fluid for the diag-
nosis of malignant effusions. Despite its utility as a serum marker
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Table 5 Prediction of the histological type of malignancies using discriminant analysisa
Predicted origin (number)
Adenocarcinomas Small-cell lung Squamous cell Mesotheliomas Correct
carcinomas carcinomas classification
Observed origin (number)
Adenocarcinomas (154) 148 1 4 1 96.1%
Small-cell lung carcinomas (13) 1 12 0 0 92.3%
Squamous cell carcinomas (11) 4 0 7 0 63.6%
Mesotheliomas (11) 9 0 0 2 18.2%
Correct prediction 91.4% 92.3% 63.6% 66.6% Total: 89.4%
aCYFRA, SCC and NSE were significantly contributive (P < 0.00001) unlike CEA, CA 72-4, CA 15-3 and CA 19-9 (P > 0.01).
Table 6 Prediction of the organ of origin of adenocarcinomas using discriminant analysisa
Predicted origin (number)
Breast Lung Digestive Ovary Correct
classification
Observed origin (number)
Breast (50) 40 10 0 0 80.0%
Lung (38) 13 19 4 2 50.0%
Digestive (11) 1 3 7 0 63.6%
Ovary (6) 3 1 0 2 33.3%
Correct prediction 70.2% 57.6% 63.6% 50% Total: 64.8%
aCEA, CA 15-3, CA 19-9 and NSE were significantly contributive (P < 0.001) unlike CYFRA, CA 72-4 and SCC (P > 0.1).for the management of ovarian cancer, carbohydrate antigen 125
was not included in our study because of its poor diagnostic speci-
ficity in pleural effusions (Ferroni et al, 1990; Rapellino et al,
1990; Zeimet et al, 1996). Since a high diagnostic specificity is
essential for the clinical use of tumour markers, we first defined
highly specific thresholds for each marker. Empyemas were
excluded from our series since, in agreement with several reports
(Klockars et al, 1980; Garcia-Pachon et al, 1997; Villena et al,
1998) we previously observed high false-positive rates for CEA,
but also for CYFRA (Salama et al, 1998) in these fluids. This
exclusion is not prejudicial because cytological and bacteriological
analyses of pleural fluid easily identify these effusions and overall,
malignancy is very rarely associated with this clinical presentation
(Sahn, 1988). The very high and isolated levels of NSE found in
the two cases of rheumatoid arthritis are in perfect agreement with
the observation of Nyberg et al (1996) who described such an
increase in 14 out of 17 patients.
In malignant effusions, comparative analysis highlighted the
similar diagnostic performances of CEA, CA 72–4, CA 15–3 and
CYFRA, clearly superior to those of CA 19–9, NSE and SCC. The
diagnostic sensitivity for pleural CEA was concordant with those
described in previous studies, confirming its utility in carcinomas
(Rapellino et al, 1990) and its non-expression in mesotheliomas
(Mezger et al, 1994). Few studies on pleural fluid have integrated
CA 72–4 (Ferroni et al, 1990, Villena et al, 1996) and our results
confirmed the high sensitivity of CA 72–4 in all types of adeno-
carcinomas, but we also noted high levels in squamous cell carci-
nomas. Similarly, as previously described (Ferroni et al, 1990,
Romero et al, 1996; Villena et al, 1996), we observed high values
of CA 15–3 in adenocarcinomas and not only in those of breast
origin. Furthermore, compared to CEA and CA 72–4, CA 15–3
showed an atypical pattern in mesotheliomas, with a sensitivity of
45.5%, in agreement with the results of Villena et al (1996). The
data published for pleural CYFRA are more controversial, notably
concerning the thresholds and the overall sensitivity which is
described as either higher (Satoh et al, 1995) or lower than the
sensitivity of CEA (Romero et al, 1996). Confirming our prior
study (Salama et al, 1998), we observed similar sensitivities for
pleural CEA and pleural CYFRA but above all, a high sensitivity
for pleural CYFRA in mesotheliomas.
The most meaningful part of the present study was the evalua-
tion of various combinations of these markers. The optimal panel
was CEA + CA 15–3 + CYFRA + NSE. It led to very high
diagnostic performance: sensitivity of 88.4% for all the malignant
effusions and 94.4% for non-lymphomatous effusions, with a
specificity of 95%. Therefore, these four markers showed a very
large diagnostic spectrum and only a few types of carcinomas in
our series remained undetectable (kidney adenocarcinoma, lung
and digestive carcinoid tumour). Even though other carcinomas,
not represented in our series, could benefit from the same
approach, such as prostate cancer with the pleural assay of
prostate-specific antigen (Cascinu et al, 1997; Brown et al, 1998)
or liver cancer with a-fetoprotein (Cascinu et al, 1997), the
systematic use of the latter markers is not recommended because
these carcinomas are only exceptionally involved in metastatic
pleural effusions. On the contrary, lymphomas are more frequently
involved but our panel, based on epithelial markers, was inade-
quate for their diagnosis. Most of the markers were very low in
lymphomas (CEA, CA 19–9, CYFRA and SCC) or rarely and
moderately increased (CA 15–3). However, two high values of CA
72–4 and one of NSE were observed in patients with lymphomas.
Few data concerning lymphomas are available but high values of
CA 72–4 have already been described (Ferroni et al, 1990).
Finally, our sensitivities are clearly higher than those previously
determined for epithelial malignancies: 73.5% with CEA + CA
72–4 (Ferroni et al, 1990), 71% with CEA and CA 15.3 (Romero
et al, 1996) and 78% with CEA + CA 15–3 + CA 72–4 (Villena et
al, 1996). Moreover, the sensitivity remained high in cytologically
negative effusions since 83.9% of non-lymphomatous effusions
were positive with at least one marker of the panel. In the groups
of adenocarcinomas and mesotheliomas, very similar sensitivities
were observed when all the effusions were considered or only the
effusions with a negative cytology. In the groups of small-cell and
squamous cell lung carcinomas, not enough patients had effusions
with a negative cytology to permit the evaluation of pleural
markers in this particular context. However, the sensitivity of the
panel was high in cytologically positive effusions and it is highly
probable that tumour markers remain efficient in cytologically
negative effusions as it was evidenced in adenocarcinomas and
mesotheliomas. Assuming that malignancy occurs in about 15%
to 25% of pleural effusions (Serre et al, 1990; Fenton and
Richardson, 1995; Ferrer et al, 1996; Villena et al, 1996), the nega-
tive and positive predictive values for the diagnosis of non-
lymphomatous malignant effusions, determined with a theoretical
prevalence of 20% and our diagnostic indexes, reach 98.7% and
82.6% respectively. Consequently, this diagnostic approach
appears to be of great interest in the event of a negative or a suspi-
cious cytology. It gives an accurate and non-invasive biological
criterion to rapidly orient the management of patients towards
more invasive procedures such as diagnostic and/or therapeutic
thoracoscopy. Markers can also be very useful in patients with a
pleurisy that remains idiopathic despite exhaustive evaluations
(more than 10% of pleurisies), since these patients are at risk of
developing a malignant pleurisy (Leslie and Kinasewitz, 1988;
Harris et al, 1995; Ferrer et al, 1996). The cost of these tests is
moderate, equivalent to a chest radiography, moreover it can be
decreased by using a gradual approach, first assaying the most
sensitive markers of the panel.
From a more fundamental point of view, pleural fluid appears as
a particularly suitable medium to study the release of tumour
markers by cancerous cells. In several patients, very low values of
markers were found in serum and extremely high concentrations in
pleural fluid (data not shown). One can hypothesize that some
cellular clones of the primary tumour able to secrete these tumour
markers also developed a high metastatic potential, the tumour
marker being involved in the process or not. Moreover, recent
studies reported that natural antibodies (Hilgers, 1998) and active
specific immunotherapy against tumour markers belonging to the
group of epithelial mucins were protective against metastatic
progression, patients with a high serum level of mucin before
immunotherapy showing a poor prognosis (Maclean et al, 1997).
These observations suggest that, beyond its diagnostic interest,
pleural assay of some tumour markers could have some prognostic
value.
We had hoped that the markers would predict the histological type
or even the origin of the tumour. The most convincing results were
obtained for the identification of small-cell lung carcinomas in
which discriminant analysis showed NSE, SCC and CYFRA to be
the most significant markers. The utility of pleural NSE to differen-
tiate non-small-cell lung carcinomas from small-cell lung carci-
nomas was previously reported (Shimokata et al, 1989). Paone et al
(1996) reached the same conclusion by discriminant analysis using
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sponding to the assay of cytokeratins 8, 18 and 19 and showing a
performance similar to that of CYFRA (Plebani et al, 1995).
Approximately 20% of malignant effusions correspond to
metastatic carcinomas of unknown primary site, essentially adeno-
carcinomas, and pleura account for 10% of the sites of tumour
involvement on initial presentation (Lembersky and Thomas,
1996). Therefore, it was of interest to evaluate the prediction of the
organ of origin by pleural tumour markers. The 64.8% of correct
prediction we obtained did not appear as sufficiently discrimina-
tive to orient the search for the primary site. In contradiction with
the report of Cascinu et al (1997), which described a high speci-
ficity for CA 19–9 and CEA in digestive cancers, our results did
not confirm the organ-specificity of the markers. Only the devel-
opment of more tissue-specific markers will permit the organ of
origin of metastatic adenocarcinomas to be efficiently predicted.
In conclusion, from a large series of pleural effusions we
demonstrated the high sensitivity and the broad spectrum of the
association CEA, CA 15–3, CYFRA and NSE for the diagnosis of
malignancy. In pleurisies with a negative cytology, these assays
are particularly useful when the clinical presentation cannot
clearly exclude an underlying malignancy. Persistent pleurisies
also constitute a relevant indication for tumour marker assays. A
multicentric and prospective study with this panel would be very
helpful to definitively establish the place of these markers in the
strategy for the management of pleural effusions. Their putative
prognostic value also deserves further investigation.
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